Continent involved in just 1 per cent of trials despite highest rate of new infections
Africa is drastically underrepresented in clinical trials focusing on Hepatitis B, a study has found, despite the continent accounting for most of the world’s new infections.
The study, published in The Lancet Gastroenterology and Hepatology this month, scoured global clinical trial registries for Hepatitis B virus (HBV) intervention trials.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.